Multiple myeloma

Multiple myeloma is a hematologic malignancy of plasma cells. Treatment typically combines proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and increasingly BCMA-directed therapies. Line of therapy, transplant eligibility, and prior exposure guide regimen selection documented in FDA-approved combination labels.

The landscape includes legacy IMiDs facing generic entry timelines disclosed in SEC filings, CD38 antibodies such as daratumumab, and BCMA-targeted bispecifics and CAR-T therapies in FDA databases. Competition occurs across lines of therapy with evidence from randomized trials—not unsourced revenue rankings.

• Bristol Myers Squibb
• Amgen

• Drug profileDarzalex (daratumumab)

• FDA databases track expanding combination regimens in newly diagnosed and relapsed disease.
• ClinicalTrials.gov registers BCMA bispecific and CAR-T studies across multiple sponsors.
• SEC filings discuss patent expiry and lifecycle management for legacy myeloma franchises.